In summary, we present the ratio between ID1 and noggin expression as a new marker for prognosis of patients with CRC, and our data strongly imply that application of BMP‐9 or induction of its expression in the liver should be a promising new strategy for future therapy approaches against initiation and progression of CRC in patients. The gene discussed is NOG; the disease is colorectal carcinoma.